List of Excipients in Branded Drug SODIUM FLUORIDE F 18

Generic Drugs Containing SODIUM FLUORIDE F 18

Company	Ingredient	NDC	Excipient
NCM USA Bronx LLC	sodium fluoride f 18	24445-623	SODIUM CHLORIDE
Biomedical Research Foundation of Northwest Louisiana	sodium fluoride f-18	24562-002	SODIUM CHLORIDE
PETNET Solutions Inc	sodium fluoride f 18	40028-512	SODIUM CHLORIDE

What are the Most Frequently-Used Excipients in SODIUM FLUORIDE F 18?

# Of NDCs	Excipient
9	SODIUM CHLORIDE

Sodium Fluoride F 18 Excipient Strategy and Commercial Opportunities

Last updated: September 9, 2026

Sodium fluoride F 18 is a short-lived PET radiopharmaceutical used to image areas of altered bone formation. Its commercial value depends less on conventional formulation patents and more on reliable cyclotron production, radiochemical purity, rapid release testing, geographic distribution, reimbursement, and integration with PET imaging networks. The optimal excipient strategy is minimal: sterile water for injection, sodium chloride for isotonicity, and limited pH adjustment when required. Preservative-free, ready-to-use single-dose presentations are generally better aligned with radiopharmacy practice than multidose formulations.

What is sodium fluoride F 18?

Sodium fluoride F 18 injection contains sodium fluoride labeled with fluorine-18, a positron-emitting radionuclide. Fluorine-18 has a physical half-life of approximately 109.7 minutes, which limits shelf life and makes manufacturing, quality control, release, and delivery highly time-sensitive (National Institute of Standards and Technology, n.d.).

The drug localizes in areas of active bone turnover and is used for PET or PET/CT imaging of the skeleton. The product is administered intravenously and is generally supplied as a sterile, pyrogen-free, preservative-free solution.

Core product attributes

Attribute	Commercial relevance
Active ingredient	Sodium fluoride F 18
Dosage form	Sterile intravenous injection
Imaging modality	PET or PET/CT
Radionuclide	Fluorine-18
Physical half-life	Approximately 109.7 minutes
Primary use	Detection of osteoblastic activity and skeletal lesions
Manufacturing model	Cyclotron production followed by radiochemical synthesis and release
Typical presentation	Single-dose or patient-specific syringe/vial
Major formulation constraint	Rapid radioactive decay
Key quality attributes	Radionuclidic identity, radiochemical purity, chemical purity, sterility, endotoxin, pH, activity concentration

The short half-life creates a commercial model based on local or regional production. Conventional pharmaceutical inventory economics do not apply. A manufacturer cannot hold finished product for weeks or months, and most distribution occurs through radiopharmacies, hospital cyclotrons, or regional PET networks.

What excipients are used in sodium fluoride F 18 injection?

The most defensible excipient platform is a simple aqueous formulation. Public product labeling describes sodium fluoride F 18 injection as an aqueous sterile solution, with sodium chloride and water for injection used as formulation components in relevant products (U.S. Food and Drug Administration, 2011).

Primary excipient functions

Excipient or component	Function	Commercial assessment
Water for injection	Vehicle	Essential and low differentiation
Sodium chloride	Isotonicity adjustment	Useful for IV tolerability and product consistency
Hydrochloric acid or sodium hydroxide	pH adjustment	Process aid; usually not a principal commercial differentiator
Ethanol, where used in a validated process	Organic-solvent process component	Requires residual-solvent control and label-specific justification
Buffer system	pH control	May improve robustness but can add regulatory and radiolysis complexity
Antioxidant, where justified	Protection against radiolytic degradation	Potentially useful but must be supported by stability and safety data
Preservative	Multidose microbial control	Generally unattractive for a short-lived, single-dose PET product

The formulation should avoid unnecessary excipients. Each additional component creates a potential burden involving extractables and leachables, toxicology, compatibility with synthesis equipment, radiolysis, sterility assurance, and regulatory review.

Why preservative-free formulations are commercially preferable

Sodium fluoride F 18 products are generally prepared and administered as patient-specific doses. The product is not a conventional multidose vial intended for repeated access over an extended period. A preservative-free formulation therefore aligns with:

• Short product lifetime
• Single-patient dosing
• Low administered volume
• Radiopharmacy aseptic practices
• Reduced risk of preservative-related intolerance
• Simpler labeling and compatibility studies

A multidose strategy would have to justify repeated vial access, microbial control, in-use stability, and dose withdrawal over a period that may approach or exceed the practical radioactive lifetime of the product. The commercial benefit is limited.

What formulation strategy best supports sodium fluoride F 18 commercialization?

The preferred strategy is a sterile, isotonic, aqueous, preservative-free injection with a narrow pH range and low excipient burden.

Recommended formulation architecture

A commercially practical product would generally include:

1. Sodium fluoride F 18 in water for injection.
2. Sodium chloride at a concentration sufficient to support intravenous tolerability.
3. pH adjustment, if required by the manufacturing process.
4. No antimicrobial preservative.
5. No surfactant unless a specific container or stability issue requires it.
6. No complex buffer unless pH drift or radiolysis demonstrates a clear need.

The formulation should be designed around the radiopharmacy process rather than around conventional tablet or injectable-product excipient preferences.

Critical formulation development issues

Radiolysis

Radiolysis can produce reactive species during processing and storage. The risk increases with radioactivity concentration, container geometry, radiation exposure, oxygen availability, and storage duration. A formulation developer should evaluate:

• Radiochemical purity over the labeled shelf life
• Fluoride ion and radiolabeled impurity formation
• pH drift
• Container closure compatibility
• Impact of activity concentration
• Nitrogen or inert-gas handling, where appropriate
• Whether an antioxidant improves stability without creating new impurities

An antioxidant can be useful, but it should not be added automatically. The short half-life may make chemical degradation less commercially important than it would be for a conventional injectable. A failed radiochemical-purity specification, however, can interrupt release and cause dose cancellations.

Isotonicity

Sodium chloride can support IV tolerability and reduce the risk associated with administration of a markedly hypotonic solution. The final formulation should be evaluated for osmolality across the intended activity and volume ranges.

pH

The pH should remain within a range compatible with intravenous administration, container closure materials, and radionuclide stability. Excessive buffering can create more complexity than value, particularly where the product is manufactured, tested, and administered within several hours.

Container closure

The container system must tolerate radiation exposure and preserve sterility throughout the labeled use period. Potential systems include:

• Type I glass vials
• Polymer syringes
• Shielded patient-specific syringes
• Automated dispensing systems

The commercial decision is often driven by radiopharmacy workflow. A ready-to-administer syringe can reduce manipulation and support hospital throughput, while a vial can offer greater flexibility for dose withdrawal and assay.

What FDA regulatory status applies to sodium fluoride F 18?

Sodium fluoride F 18 injection is an FDA-approved PET radiopharmaceutical. The FDA approved sodium fluoride F 18 injection for diagnostic PET imaging of bone abnormalities in 2011 under NDA 203155, according to the FDA approval announcement and related product materials (U.S. Food and Drug Administration, 2011).

Regulatory characteristics

Regulatory issue	Assessment
FDA status	Approved PET diagnostic radiopharmaceutical
Route	Intravenous
Product type	Small-molecule radiopharmaceutical
Approval pathway	NDA-based approval for the referenced product
Biosimilar pathway	Not applicable
Generic substitution	Depends on product-specific approval and pharmacy practice
CMC focus	Radiochemical manufacture, sterility, endotoxin, radionuclidic identity, purity, assay, and release timing
Manufacturing site	Usually linked to a cyclotron and radiopharmacy operation

FDA guidance for PET drugs recognizes the need to address radioactive decay, radiochemical purity, production controls, and release testing in a manner appropriate to the product’s short half-life (U.S. Food and Drug Administration, 2019).

What is the Orange Book status of sodium fluoride F 18?

The Orange Book analysis is less commercially important for sodium fluoride F 18 than for chronic-use small-molecule drugs. The product is not generally protected by a conventional composition-of-matter patent covering a new molecular entity. Sodium fluoride is an old chemical entity, and fluorine-18 is a radionuclide generated by cyclotron production.

For an individual approved product, Orange Book status should be assessed by NDA number, sponsor, and current FDA listing. The commercial barrier is more likely to arise from manufacturing capability, local distribution, quality systems, and reimbursement than from a long period of listed formulation exclusivity.

What patents protect sodium fluoride F 18?

The core active ingredient is unlikely to support meaningful composition-of-matter exclusivity because sodium fluoride is an established inorganic compound and fluorine-18 is a radioactive isotope rather than a novel therapeutic molecule.

Potential patent categories include:

• Cyclotron target and radionuclide-production methods
• Automated synthesis equipment
• Radiopharmacy dispensing systems
• Patient-specific dose preparation
• Container and shielding systems
• PET imaging protocols
• Disease-specific interpretation or workflow methods
• Combination imaging methods
• Formulations that improve radiochemical stability

These patents generally protect processes, devices, or workflows rather than the basic sodium fluoride F 18 molecule.

How strong is the patent estate?

The patent estate for the basic drug product is likely weak relative to conventional branded pharmaceuticals. A stronger commercial position may be built around:

• Proprietary automated dose-dispensing systems
• Integrated cyclotron and radiochemistry platforms
• Quality-control automation
• Regional production and logistics
• Exclusive hospital or radiology-network contracts
• Reimbursement support and clinical workflow integration

Formulation patents would need to establish a meaningful technical effect, such as improved radiochemical purity, reduced radiolysis, longer usable time after end of synthesis, or improved compatibility with a dispensing device. A patent covering only sodium fluoride F 18 in saline would face significant validity and enforceability challenges because of the simplicity and predictability of the formulation.

When does sodium fluoride F 18 lose exclusivity?

Sodium fluoride F 18 does not have a conventional loss-of-exclusivity event comparable to a branded chronic-care drug. The core compound is old, and the principal product constraint is radioactive decay rather than patent expiry.

Exclusivity timeline

Milestone	Timing or status
Sodium fluoride as a chemical entity	Long-established
Fluorine-18 PET use	Established clinical technology
FDA approval of a sodium fluoride F 18 PET product	2011 approval milestone for NDA 203155
Conventional NCE exclusivity	Not the primary commercial issue
Patent cliff	No single core-product cliff identified
Competition	Driven by production capacity, geography, price, and service reliability

The relevant market event is entry by another approved manufacturer or compounded radiopharmacy, not expiry of a composition patent.

What generic entry risks exist for sodium fluoride F 18?

Generic entry risk is high in principle because the product has a simple formulation and an old active ingredient. The practical barriers are operational rather than molecular.

Principal entry risks

Local production capacity

Fluorine-18 must be produced near the point of use. A competitor needs access to a suitable cyclotron, targetry, radiochemistry equipment, trained personnel, validated aseptic operations, and quality-control testing.

Distribution radius

A product loses activity continuously during transport. A supplier with a distant manufacturing site may be commercially uncompetitive even if its manufacturing cost is lower.

Release testing

The manufacturer must complete identity, purity, assay, sterility-related controls, endotoxin testing, and other release activities within a short period. The ability to release safely and consistently is a key barrier.

PET capacity

Demand depends on PET/CT scanner availability, radiologist capacity, scheduling, and payer coverage. A supplier cannot create sustained demand through formulation alone.

Reimbursement

Coverage and payment policies affect the economics of NaF F 18 PET. Medicare and commercial payer policies, hospital contracts, and bundled imaging rates can determine whether a site adopts the product.

Which companies and operating models compete in sodium fluoride F 18?

Competition generally comes from three operating models:

1. National or regional commercial radiopharmaceutical suppliers.
2. Hospital-based cyclotron and radiopharmacy operations.
3. Independent PET centers with on-site production.

Commercial suppliers compete on delivery reliability, dose accuracy, product availability, ordering systems, and geographic reach. Hospital-based operations compete through same-site availability and integration with imaging services. Independent PET centers may use internal production to reduce external supply dependence.

The competitive landscape is fragmented by geography. A company with a strong market share in one metropolitan area may have little practical influence in another because delivery time and decay make the market local.

What commercial opportunities exist for excipient suppliers?

The excipient opportunity is narrower than in conventional injectable drugs, but several areas have commercial potential.

High-value opportunities

Radiolysis-control systems

Excipient suppliers may develop validated antioxidant or oxygen-control approaches that preserve radiochemical purity during the usable product window. The opportunity is strongest where the formulation can extend dispatch distance or improve release consistency.

Ready-to-use product presentations

Patient-specific syringes, calibrated vials, and dose-management systems can reduce operator exposure and preparation time. The value lies in workflow efficiency rather than in the excipient itself.

Low-binding container systems

A validated container closure that minimizes adsorption, extractables, leachables, and radiation-related degradation can support differentiated CMC claims.

Automated compounding and dispensing

The strongest platform opportunity may combine formulation, dose assay, shielding, and dispensing. A supplier that integrates these functions can create switching costs that a simple saline formulation cannot provide.

Regional manufacturing support

Excipient suppliers can support standardized, validated formulation kits for hospital cyclotrons and radiopharmacies. These systems could reduce site-to-site variability, although each site would still need appropriate process validation and regulatory controls.

How does sodium fluoride F 18 compare with FDG and other PET drugs?

Sodium fluoride F 18 competes for scanner time, radiopharmacy capacity, and imaging budgets rather than only for prescription volume.

Product	Primary imaging target	Commercial distinction
Sodium fluoride F 18	Bone turnover	Strong skeletal uptake; useful for osseous disease assessment
Fluorodeoxyglucose F 18	Glucose metabolism	Broad oncology, neurology, and inflammation use
F 18 amyloid agents	Amyloid plaques	Specialized neuroimaging
F 18 prostate-specific membrane antigen agents	PSMA expression	Prostate cancer imaging
Ga-68 or other radiometal agents	Disease-specific targets	Different production and logistics profile

FDG generally has broader clinical utilization. Sodium fluoride F 18 may compete effectively where the clinical question is skeletal disease and where PET/CT is preferred over conventional bone scintigraphy or other imaging methods.

The excipient strategy for sodium fluoride F 18 should therefore support low cost, high availability, rapid preparation, and dependable scheduling rather than premium formulation complexity.

What manufacturing and intellectual-property barriers matter most?

The principal barriers are:

• Cyclotron ownership or access
• Targetry and radiochemistry validation
• Aseptic processing
• Radioactive-material licensing
• Qualified personnel
• Short release timelines
• Transport and shielding
• Reliable PET/CT demand
• Hospital and radiology contracts
• Regulatory compliance across production sites

These barriers can provide practical protection even where patent protection is limited. A supplier with validated local production and dependable delivery may retain customers despite the availability of technically substitutable products.

What litigation or Paragraph IV challenges affect sodium fluoride F 18?

There is no widely recognized, product-defining Paragraph IV campaign comparable to those involving major oral drugs. Paragraph IV risk would be relevant only if a listed patent created a meaningful barrier to an abbreviated applicant or another competing sponsor.

For sodium fluoride F 18, disputes are more likely to involve:

• Manufacturing patents
• Automated dispensing technology
• Trade secrets
• Contractual supply rights
• Hospital purchasing agreements
• Regulatory compliance
• Product-quality events
• Trademark or labeling issues

Settlement agreements are unlikely to define the market in the way they do for high-revenue chronic therapies. The commercial importance of a dispute would depend on whether it affects a regional production platform or a widely deployed dispensing system.

How should investors evaluate revenue exposure?

Revenue exposure should be modeled by operational volume rather than by patent duration.

Key variables include:

• Number of active cyclotrons
• Daily patient doses
• Average activity per dose
• PET/CT scanner utilization
• Product price per dose
• Delivery radius
• Failed-dose rate
• Release failures
• Hospital contract duration
• Reimbursement by payer
• Share of imaging revenue attributable to the radiopharmaceutical

A formulation improvement that reduces failed doses or extends the practical delivery radius can have measurable economic value. A minor excipient change without a demonstrated operational benefit is unlikely to justify a premium.

Key Takeaways

• Sodium fluoride F 18 is a short-lived PET radiopharmaceutical with a formulation centered on water for injection and sodium chloride.
• Preservative-free, single-dose presentations are generally better aligned with radiopharmacy use than multidose products.
• The most important formulation risks are radiolysis, pH control, container compatibility, sterility, endotoxin, and rapid release testing.
• The core molecule is unlikely to support a strong composition-of-matter patent estate.
• Commercial defensibility depends more on cyclotron access, manufacturing quality, delivery radius, PET-network relationships, and workflow integration.
• Excipient opportunities are strongest in radiolysis control, container systems, ready-to-use syringes, and automated dispensing.
• Generic or competing entry is technically feasible, but local production and logistics create significant practical barriers.
• There is no conventional biosimilar risk because sodium fluoride F 18 is a small-molecule radiopharmaceutical, not a biologic.
• No single patent-expiry date is likely to define market entry. Regional supply economics and regulatory execution are more important.

FAQs

Is sodium fluoride F 18 a generic drug?

It is a small-molecule radiopharmaceutical based on an established chemical entity. Whether a specific product is classified as a generic depends on its FDA approval pathway and product-specific regulatory status.

Can sodium fluoride F 18 contain preservatives?

It can be theoretically formulated with a preservative, but a preservative-free, patient-specific presentation is generally more consistent with its short half-life and radiopharmacy use.

Can an excipient extend the shelf life of sodium fluoride F 18?

An excipient may improve radiochemical stability during the usable period, but it cannot overcome the physical decay of fluorine-18, which has a half-life of approximately 109.7 minutes.

Are formulation patents important for sodium fluoride F 18?

They can matter if they demonstrate a measurable improvement in radiochemical purity, delivery distance, container compatibility, or dispensing efficiency. A basic saline formulation is unlikely to provide strong patent differentiation.

Is sodium fluoride F 18 exposed to biosimilar competition?

No. Biosimilar regulation applies to biologic products. Sodium fluoride F 18 is a radioactive small-molecule diagnostic agent.

References

1. National Institute of Standards and Technology. (n.d.). NIST radionuclide half-life measurements: Fluorine-18. https://www.nist.gov/

2. U.S. Food and Drug Administration. (2011). FDA approves sodium fluoride F 18 injection for PET imaging of bone. https://www.fda.gov/

3. U.S. Food and Drug Administration. (2019). PET drugs: Current good manufacturing practice and quality systems guidance. https://www.fda.gov/

4. United States Pharmacopeia. (2024). General chapter <823>: Positron emission tomography drugs for compounding, dispensing, and repackaging. In United States Pharmacopeia and National Formulary. United States Pharmacopeial Convention.

5. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm